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ess: julia.johansen@poSummary Background: YKL-40, a growth factor for fibroblasts and vascular
endothelial cells, is secreted by macrophages and neutrophils. Elevated serum
YKL-40 is found in patients with diseases characterized by inflammation, tissue
remodelling and ongoing fibrosis. The aim was to evaluate whether macrophages and
giant cells in the granulomatous sarcoid lesions of patients with pulmonary
sarcoidosis produce YKL-40 and to determine whether serum YKL-40 in these
patients were associated with disease activity.
Methods: Serum YKL-40 was determined by radioimmunoassay in 27 patients with
a histological diagnosis of pulmonal sarcoidosis. Immunohistochemical staining for
YKL-40 antigen was performed in five biopsies with pulmonary sarcoid lesions. Serum
YKL-40 was likewise measured in 173 healthy age-matched control subjects.
Results: Mononuclear cells/macrophages and giant cells in pulmonary sarcoid
granulomas expressed YKL-40 protein. Serum YKL-40 was higher in patients with
pulmonary sarcoidosis compared to controls (Po0:001) and 63% had elevated serum
YKL-40. There was a positive correlation between serum YKL-40 and serumElsevier Ltd. All rights reserved.
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Serum YKL-40 in pulmonary sarcoidosis 397angiotensin converting enzyme (rho ¼ 0:55; P ¼ 0:0053). Patients with serum YKL-
404median value in the patient group had lower carbon monoxide diffusion capacity
corrected for alveolar volume (DLCO/VA) than patients with serum YKL-40pthe
median value (P ¼ 0:015).
Conclusions: Serum YKL-40 may be a novel biomarker of sarcoid disease activity
and ongoing fibrosis in patients with pulmonary sarcoidosis.
& 2004 Elsevier Ltd. All rights reserved.Introduction
YKL-40, a member of family 18 glycosyl hydro-
lases,1–5 is a heparin and chitin-binding lectin4,5
without chitinase activity.1,5 The gene for YKL-40 is
known6 and located on chromosome 1, and its
crystal three-dimensional structure has been de-
scribed.7 However, the site and mode of binding of
YKL-40 to cell surface receptors is still unknown.
The biological function of YKL-40 is not known in
detail. One study has shown that YKL-40 is a growth
factor for fibroblasts and acts synergistically with
insulin-like growth factor 1 in stimulating the
growth of fibroblasts.8 YKL-40 is also a growth
factor for chondrocytes and synovial cells,9 is a
chemo-attractant for endothelial cells and stimu-
lates migration of these cells at a level comparable
to basic fibroblast growth factor.10 Furthermore,
YKL-40 modulates vascular endothelial cell
morphology by promoting the formation of branch-
ing tubules, indicating that YKL-40 may play a role
in angiogenesis by stimulating the migration and
reorganization of vascular endothelial cells.10
YKL-40 is secreted in vitro by activated neutro-
phils,11 macrophages during late state of differ-
entiation,6,12,13 arthritic chondrocytes1 and cancer
cells.14,15 In vivo YKL-40 is expressed by macro-
phages in inflamed synovial membrane13,16,17 and
atheromatous plagues18 and by macrophages and
giant cells in the media of arteritic vessels of patients
with giant cell arteritis.19 The pattern of YKL-40
expression in normal and disease states suggests that
the protein plays a role in inflammatory processes,
remodelling of the extracellular matrix and develop-
ment of fibrosis. Elevated serum concentrations of
YKL-40 are found in patients with rheumatoid
arthritis,2,17,20,21 giant cell arteritis,19 inflammatory
bowel disease,22,23 bacterial infections,24,25 liver
fibrosis26–28 and metastatic cancer.29–32
Sarcoidosis is a multisystem granulomatous dis-
order of unknown etiology characterized by the
formation of noncaseating epithelioid cell granulo-ilage glycoprotein-39 (HC
rotein (Gp38k),4 Chitinase
ssing protein 39 kDa (brp-mas.33 Although essentially all organs of the body
may be affected by sarcoidosis, the lungs are the
most commonly involved.34 Disease activity is
accompanied by chronic inflammation resulting in
mononuclear cell infiltrates and formation of
granulomas. Even in the early phase of granuloma
formation, a fibrotic response may be observed. In
some patients with sarcoidosis, the fibrotic re-
sponse can produce substantial and irreversible
organ dysfunction and remodelling. A significant
fraction of patients with chronic active pulmonary
sarcoidosis succumb to respiratory failure.
The natural course of sarcoidosis is unpredictable
in the individual patient. In most cases pulmonary
involvement clears or stabilizes in more than 80% of
affected patients.35 However, permanent severe
pulmonary dysfunction may occur and accounts for
most morbidity and mortality.35 Many attempts
have been made to find serological biomarkers of
disease activity in pulmonary sarcoidosis, which
could help identify patients at risk for irreversible
organ damage, e.g. lung fibrosis. Since the early
1980’s, measurement of serum peptidyl-dipepti-
dase A also known as serum angiotensin-converting
enzyme (SACE) has been used routinely to monitor
disease activity in patients with sarcoidosis.36–38 In
patients with sarcoidosis, ACE is produced predo-
minantly in the epithelioid cells/macrophages in
sarcoid granulomas.39 Therefore, the SACE concen-
tration reflects the total granuloma mass,40 but is
not useful as a prognostic parameter of significant
irreversible organ dysfunction.38
The aim of the present study was threefold:
Firstly, to evaluate whether mononuclear cells/
macrophages and giant cells in sarcoid granulomas
of patients with pulmonary sarcoidosis produce
YKL-40. Secondly, to evaluate the distribution
pattern of serum YKL-40 levels in patients with
sarcoidosis. Thirdly, to search for an association
between serum YLK-40 and disease activity.Methods
Patients: The hospital records of 222 patients with
a diagnosis of sarcoidosis who had been admitted to
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Hospital in the period 1978–1995 were retrospec-
tively investigated and data from the time of
diagnosis and at succeeding follow-up investiga-
tions were recorded. In the period 1985–1995 the
patients were systematically investigated with
pulmonary function tests and blood tests at
diagnosis and at out-patients clinic follow-up
investigations after 1,3,6, 9 and 12 months and
then once per year. This was not done according to
a research protocol, but as a part of the clinical
routine. In 27 of these patients blood specimens
were available. Consequently we used this
pre-existing material in the present study, which
should be considered as a hypothesis generating
pilot study. The study included 27 patients (22 men)
with a median age of 41 years (range 24–64) with a
diagnosis of pulmonary sarcoidosis confirmed by
histology. Eight patients had manifestations of
extrapulmonary sarcoidosis. The median disease
duration was 12 months (range 0–198). During the
observation period 12 patients were treated with
prednisolone, and six of these were treated at the
time of blood sampling with doses of 2.5–10mg/
daily. These patients had been tapered of from
doses of 30–40mg/daily over a period of 3 months
to 7 years. None of the patients had cancer, liver
disease, or symptoms/signs of non-sarcoid inflam-
matory joint disease.
Control subjects: Serum YLK-40 levels were
determined in 173 healthy age-matched subjects
(median age 34 years, range 24–64).41 SACE was
measured in 74 healthy adult subjects, members of
the hospital staff and blood donors aged 20–60
years.
Biochemical analysis: Blood samples were al-
lowed to clot at room temperature and centrifuged
at 2000 g for 10min. Serum samples were stored
within 3 h at 80 1C. Plasma immunoglobulins (IgG,
IgA, IgM), plasma calcium and erythrocyte sedi-
mentation rate (ESR) were analyzed by routine
methods. Serum YKL-40 was measured by an
in-house radioimmunoassay (RIA) using rabbit anti-
body against human YKL-40.2 SACE was analyzed by
a spectrophotometric method.42
Lung function tests: Spirometry, carbon monox-
ide diffusion capacity (DLCO) and alveolar volume
(VA) were measured on VMAX 6209 (Sensor Medics
Corporation, Yorba Linda, California, USA). DLCO
was measured by the single-breath method and VA
by single-breath dilution of helium. The results
were expressed as DLCO corrected for VA (DLCO/
VA). Chest X-ray was not available in synchrony
with blood sampling and lung function test.
Immunohistochemical staining for YKL-40: By
flexible bronchoscopy, transbronchial lung biopsyspecimens were obtained from five patients with
pulmonary sarcoidosis in the initial diagnostic
evaluation. The specimens were fixed in formalde-
hyde and stained using a conventional peroxidase
staining technique for monoclonal antibodies
(DAKO Envision System/HR, DK-1309, Copenhagen).
A monoclonal antibody against human YKL-40 was
used in an IgG concentration of 7 mg/l. A
3,30-diamino-benzidine chromogen solution was
used as colour substrate and recognized as a brown
colour. Counterstaining was performed with Mayer
haematoxylin.
Statistical analysis: Statistical analysis was per-
formed with the Statview 5.0 for the MacIntosh
using non-parametric statistics. The significance of
differences was assessed by Mann–Whitney’s test
for unpaired differences correlations by Spear-
man’s rho test. P-valuesp0.05 were considered to
be significant.Results
In lung biopsy specimens from all five patients with
pulmonary sarcoidosis, positive staining for YKL-40
antigen was found in macrophages and giant cells in
sarcoid granulomas and in macrophages and neu-
trophils in areas with inflammation (Fig. 1). There
was no YKL-40 staining in lymphocytes or fibro-
blasts.
Median serum YKL-40 concentration in sarcoido-
sis patients was 420 mg/l (range 106–1000),
significantly (Po0:001) higher compared to controls
(median 100mg/l; 5–95 percentile: 60–214mg/l).
Serum YKL-40 was elevated in 17/27 (63%) of the
sarcoidosis patients (i.e. above the 95% percentile
in controls). All patients had normal haemoglobin
levels (mean 9.3mmol/l (range 7.8–10.5).
The 95% CI for SACE in healthy adult subjects was
30–115 U/l. Median SACE level in sarcoidosis pa-
tients was 109 U/l (range 48–448). SACE was
elevated (i.e. above the 95% percentile in controls)
in 13/27 (48%) of sarcoidosis patients. Serum YKL-
40 concentrations displayed a positive correlation
to SACE (rho ¼ 0:55; P ¼ 0:0053) (Fig. 2) and an
inverse correlation to DLCO/VA (rho ¼ 0:40;
P ¼ 0:04). Serum YKL-40 and SACE were not
correlated to ESR, haemoglobin, plasma aspartate
aminotransferase, plasma alkaline phosphatase,
plasma calcium, plasma phosphate, plasma immu-
noglobulins, FEV1, FVC and TLC.
Patients with serum YKL-40 concentrations of
4420 mg/l (i.e. above the median serum YKL-40
level of all the patients) had significantly lower
DLCO/VA than patients with serum YKL-40 below or
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Figure 2 Correlation (Spearman’s rho) between serum
YKL-40 (mg/l) and serum angiotensin converting enzyme
(SACE, U/l) in 27 patients with pulmonary sarcoidosis.
Figure 1 Light micrograph of immunohistochemical staining for YKL-40 in a lung biopsy specimen from a patient with
pulmonary sarcoidosis (magnification 20). Bar=50 mm. Arrow=YKL-40 positive giant cell. Arrow head=YKL-40 positive
mononuclear cell.
Serum YKL-40 in pulmonary sarcoidosis 399equal to the median (4.37ml/min mmHg/l (range
3.54–5.73) vs. 5.24 (3.70–6.62), P ¼ 0:015) (Fig. 3,
right). No difference in DLCO/VA was found in
patients with SACE levels 4109 U/l (i.e. above the
median SACE level of all the patients) compared to
patients with SACEp109U/l (Fig. 3, left). If the
patients were divided according to DLCO/VA,
patients with a DLCO/VA below the median level
of all patients (i.e.o4.83ml/min mmHg/l) had
significantly higher median serum YKL-40 level
(535 mg/l (range 112–1000)) compared to median
serum YKL-40 level in patients with a high DLCO/VA
(204 mg/l (106–880), P ¼ 0:026). The corresponding
median values for serum SACE was 131 U/l
(50–448U/l) vs. 103 (48–176), P ¼ 0:04: Serum
YKL-40 was not related to the radiographic stages
of the Chest X-ray that was not available in
synchrony with blood sampling and lung function
test.Patients treated with prednisolone during the
observation period had a trend towards higher
serum YKL-40 levels than untreated patients
(P ¼ 0:14), and there was a borderline correlation
between the cumulated dose of prednisolone and
serum YKL-40 (rho ¼ 0:38; P ¼ 0:053). There was no
difference in serum YKL-40 between smokers
(495 mg/l (166–780), N ¼ 8) and non-smokers
(345 mg/l (106–1000), N ¼ 19; P ¼ 0:33).Discussion
This is the first study of YKL-40 in patients with
sarcoidosis. Using immunohistochemical staining of
lung biopsies from patients with pulmonary sarcoi-
dosis we found YKL-40 expression by macrophages
and Langhans0 giant cells in the sarcoid granulomas
and by macrophages and neutrophils in areas with
inflammation. We then determined serum YKL-40 in
a small series of patients with pulmonary sarcoi-
dosis and found elevated serum levels in 2/3 of the
patients. Interestingly, the highest serum YKL-40
concentrations were found in patients with low
DLCO/VA. In contrast, SACE, which is used as
routine follow-up parameter, could not discrimi-
nate between patients with low or high DLCO/VA.
The definite biological function of YKL-40 is
unclarified. YKL-40 probably has a function in both
acute and chronic inflammatory processes and YKL-
40 initiates a signalling cascade in fibroblasts that
lead to increased cell proliferation,8 suggesting
that YKL-40 also has a role in conditions leading to
tissue fibrosis. In patients with liver diseases of
different aetiology elevated serum YKL-40 reflects
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Figure 3 Box plots of diffusion capacity corrected for alveolar volume (DLCO/VA, ml/min mmHg/l) in 27 patients with
pulmonary sarcoidosis with SACE below and above the median value (109U/l) in the entire series (right) and with serum
YKL-40 below and above the median value (420 mg/l) in the entire series (left). The 5th, 25th, 50th, 75th and 95th
percentiles are shown.
J.S. Johansen et al.400liver fibrosis,26–28 and high serum YKL-40 in patients
with alcoholic liver disease predicts short survi-
val.28 Whether YKL-40 is involved in the pathogen-
esis of sarcoidosis and in progression of organ
fibrosis in patients with sarcoidosis remains to be
clarified. Sarcoidosis is associated with up-regu-
lated local and systemic inflammatory immune
responses.33 No specific common antigen has been
identified in patients with sarcoidosis, and it is
possible that more than one antigen may be
involved in the T-cell response. YKL-40 has been
demonstrated to be an autoantigen in patients with
rheumatoid arthritis. YKL-40 derived peptides,
which bind with high affinity to the rheumatoid
arthritis associated HLA-DR1 and DR4, are recog-
nized by peripheral T cells from patients with
rheumatoid arthritis, and these T cells show a
proliferative response to YKL-40 peptides.43–45 In
BALB/c mice, YKL-40 induces a chronic relapsing
arthritis, which can be delayed and suppressed by
inducing tolerance through nasal administration of
YKL-40.43,44
Future studies should verify whether the YKL-40+
macrophages in patients with pulmonary sarcoido-
sis belong to the CD14+, CD16+ types. YKL-40+
monocytes/macrophages in peripheral blood and
synovium from patients with rheumatoid arthritis
are different from ‘‘classic’’ monocytes/macro-
phages and circulating dendritic precursors. The
YKL-40+ cells are CD16+, have a dim expression of
CD14 and resemble the CD14+, CD16+ monocyte
population described by Ziegler-Heitbrock.46
The role of the CD14+, CD16+ cell type remains to
be determined. They are believed to be of
pro-inflammatory type and a more mature version
of monocytes with properties of tissue macro-
phages. Interestingly, the CD14+, CD16+ monocytes
are increased in numbers in patients with rheuma-
toid arthritis,16 sepsis,47 tuberculosis48 and solid
tumours.49The result of the present study of YKL-40 in
patients with pulmonary sarcoidosis suggests that it
would be interesting to study changes in serum
YKL-40 concentrations in a longitudinal setting of
patients with sarcoidosis. It needs to be clarified
whether the serum YKL-40 level in combination
with lung function tests and other potential
serological parameters of disease activity (e.g.
SACE, sIL-2R, TNFa; sTNF-RII) could be useful to
monitor in order to identify at an early stage
patients with sarcoidosis at high risk of irreversible
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